CRDL

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on developing anti-inflammatory and anti-fibrotic therapies for cardiovascular disease. Headquartered in Oakville, Ontario, Canada, the company's lead product candidate is CardiolRx, a pharmaceutically produced cannabidiol (CBD) formulation designed to treat heart inflammation and fibrosis. Cardiol is conducting clinical trials evaluating CardiolRx for acute myocarditis and acute respiratory distress syndrome (ARDS). The company utilizes nanotechnology to enhance CBD bioavailability and therapeutic efficacy.